Key facts
- Bio ReFine’s last known valuation is $6.5M (Feb 2023).
- It has raised $2.5M; the latest was Seed Round ($500K) in Oct 2025.
- Notable investors include Peregrine Ventures, Incentive Incubator.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Bio ReFine
- ·The full record, as it builds
Funding rounds
No funding rounds for Bio ReFine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Bio ReFine
Developer of an endovascular annuloplasty remodeling system designed to assist in the repair of the mitral and tricuspid heart valves. The company's implant-less annuloplasty allows heart valve repair in a minimally invasive procedure and uses a standard endovascular approach and the procedure is safe, repeatable, and does not prevent ancillary procedures, enabling healthcare professionals to reduce risks in surgery.
- Sector
- Healthcare
- HQ
- Tel Aviv, Israel
- Employees
- 2
- Ownership
- Privately Held (backing)
Bio ReFine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bio ReFine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bio ReFine in its N-PORT filings yet. We sweep new filings monthly.